Rüegg C - Search Results

1

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.

Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Rüegg C, et al. Nat Med. 1998 Apr;4(4):408-14. doi: 10.1038/nm0498-408. Nat Med. 1998. PMID: 9546785

2

Soft tissue sarcoma therapy: prospects for future studies.

Lejeune FJ, Liénard D, Rüegg C, Leyvraz S. Lejeune FJ, et al. Among authors: ruegg c. Eur J Surg Oncol. 1995 Oct;21(5):474-7. doi: 10.1016/s0748-7983(95)96713-3. Eur J Surg Oncol. 1995. PMID: 7589588 Review. No abstract available.

3

Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors.

Schienk S, Liénard D, Gerain J, Baumgartner M, Lejeune FJ, Chiquet-Ehrismann R, Rüegg C. Schienk S, et al. Among authors: ruegg c. Int J Cancer. 1995 Nov 27;63(5):665-72. doi: 10.1002/ijc.2910630511. Int J Cancer. 1995. PMID: 7591283 Clinical Trial.

4

Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.

Gérain J, Liénard D, Pampallona S, Baumgartner M, Rüegg C, Buurman WA, Eggermont A, Lejeune F. Gérain J, et al. Among authors: ruegg c. Cytokine. 1997 Dec;9(12):1034-42. doi: 10.1006/cyto.1997.0247. Cytokine. 1997. PMID: 9417816 Clinical Trial.

5

Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.

Furrer M, Altermatt HJ, Ris HB, Althaus U, Rüegg C, Liénard D, Lejeune FJ. Furrer M, et al. Among authors: ruegg c. Melanoma Res. 1997 Aug;7 Suppl 2:S43-9. Melanoma Res. 1997. PMID: 9578416

6

Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology.

Yilmaz A, Bieler G, Spertini O, Lejeune FJ, Rüegg C. Yilmaz A, et al. Among authors: ruegg c. Int J Cancer. 1998 Aug 12;77(4):592-9. doi: 10.1002/(sici)1097-0215(19980812)77:4<592::aid-ijc20>3.0.co;2-7. Int J Cancer. 1998. PMID: 9679764 Free article.

7

Clinical applications of TNF-alpha in cancer.

Lejeune FJ, Rüegg C, Liénard D. Lejeune FJ, et al. Among authors: ruegg c. Curr Opin Immunol. 1998 Oct;10(5):573-80. doi: 10.1016/s0952-7915(98)80226-4. Curr Opin Immunol. 1998. PMID: 9794839 Review.

8

Death to endothelial cells, death to melanoma?

Ruegg C, Oguey D, Lejeune F. Ruegg C, et al. Melanoma Res. 1999 Feb;9(1):2-3. Melanoma Res. 1999. PMID: 10338328 No abstract available.

9

Urokinase-type plasminogen activator inhibits alpha 4 beta 1 integrin-mediated T lymphocyte adhesion to fibronectin independently of its catalytic activity.

Olivier P, Bieler G, Müller KM, Hauzenberger D, Rüegg C. Olivier P, et al. Among authors: ruegg c. Eur J Immunol. 1999 Oct;29(10):3196-209. doi: 10.1002/(SICI)1521-4141(199910)29:10<3196::AID-IMMU3196>3.0.CO;2-N. Eur J Immunol. 1999. PMID: 10540331 Free article.

10

Disruption of integrin-dependent adhesion and survival of endothelial cells by recombinant adenovirus expressing isolated beta integrin cytoplasmic domains.

Oguey D, George PW, Rüegg C. Oguey D, et al. Among authors: ruegg c. Gene Ther. 2000 Aug;7(15):1292-303. doi: 10.1038/sj.gt.3301236. Gene Ther. 2000. PMID: 10918500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page